Cross-study comparison of maternal vaccination against infant disease
| Population | Vaccine group | Placebo group | Vaccine efficacy % (95% CI) |
| Madhi et al. [13]# | |||
| Per-protocol analysis | 1.5 (41/2765) | 2.4 (35/1430) | 39.4 (5.3–61.2) |
| Intention-to-treat analysis | 1.6 (47/2980) | 2.3 (36/1547) | 32.2 (−4.2–55.9) |
| Expanded-data intention-to-treat analysis | 2.3 (70/2980) | 4.0 (62/1547) | 41.4 (10.0–58.1) |
| Omer et al. [14]¶ | |||
| Age ≤2 months | |||
| Nepal | 1.1 (20/1820) | 1.7 (31/1826) | 35 (−14–63) |
| Mali | 0.1 (2/2064) | 0.5 (10/2041) | 80 (19–96) |
| South Africa | 0.2 (2/1026) | 1.3 (13/1023) | 85 (32–97) |
| Pooled | 0.5 (24/4910) | 1.1 (54/4890) | 56 (28–73) |
| Age ≤4 months | |||
| Nepal | 2.4 (43/1820) | 3.3 (61/1826) | 29 (−4–52) |
| Mali | 0.5 (11/2064) | 1.7 (35/2041) | 69 (38–84) |
| South Africa | 1.4 (14/1026) | 2.9 (30/1023) | 54 (13–75) |
| Pooled | 1.4 (68/4910) | 2.6 (126/4890) | 46 (28–60) |
| Age ≤6 months | |||
| Nepal | 4.1 (74/1820) | 5.8 (105/1826) | 29 (5–48) |
| Mali | 2.4 (50/2064) | 3.8 (77/2041) | 35 (8–55) |
| South Africa | 1.9 (19/1026) | 3.6 (37/1023) | 49 (12–70) |
| Pooled | 2.9 (143/4910) | 4.5 (219/4890) | 35 (19–47) |
Data are presented as percentage of infants (number/total number), unless otherwise stated. #: vaccine efficacy as reported at 90 days of age across all three population groups. ¶: cumulative data for each age group; pooled data equals the total across Nepal, Mali and South Africa.